MYD88 and diffuse large B-cell lymphoma: Enrichment in SCL and DLBCL for GAs in B-cell receptor signaling pathway CD79B (SCL: 16.7%, Systemic: 6.2%), CARD11 (SCL: 2.8%, Systemic: 7.5%), TNFAIP3 (SCL: 2.8%, Systemic: 15.8%), and MYD88 (SCL: 27.8%, Systemic: 15.5%) is reported here as well.